SELLAS shares jump 157% after company says its leukemia

SELLAS Life Sciences (SLS) shares surged 157% after reporting positive Phase 3 trial results for its leukemia vaccine, galinpepimut-S, showing a 41% reduction in death risk. The stock closed at $19.17, valuing the company at $3.9B. However, after launching a $150M stock offering, shares dropped 10-13% in after-hours trading. The trial enrolled 126 patients, with median survival of 24.0 months vs. 14.7 months for existing treatments. The company plans to file for regulatory approval in 2027.

Original reporting
Published Nov 18, 2026, 12:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 12:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$SLS
Bullish
medium confidence
Mentioned
$SLS
Relevance
8/10
AlphAI data visualization · based on quantisnow.com
Decision brief

The 30-second read

$SLSBullishMed
01

Why it matters

The Phase 3 survival readout is the primary catalyst for the outsized rally, but the concurrent equity sale introduces dilution and liquidity overhang, producing after-hours drawdown and likely continued volatility until offering details and subsequent clinical/filing milestones clarify value.

02

Market read

Traders must weigh a headline-positive Phase 3 survival result against immediate dilution from a same-day equity offering, which the article links to after-hours weakness.

03

What to watch

The article notes no peer review and missing confidence intervals, plus uncertainty around post-trial therapies and secondary endpoint timing, which can drive rapid sentiment reversals after the initial headline spike.

Relevance 8/10Novelty 8/10Timing: after-hours reaction to the same-day $150M offering following Phase 3 topline

Background

SELLAS (SLS) announced Phase 3 REGAL topline results for its leukemia vaccine galinpepimut-S (GPS) in acute myeloid leukemia, then launched a $150 million underwritten stock offering the same day.

Company-level read

Ticker impact

$SLSBullishMedium confidence
Context

SELLAS reported Phase 3 REGAL results for galinpepimut-S, cutting death risk by 41% (HR 0.59, p=0.035), triggering a 156.6% one-day jump and a same-day $150M offering.

Expected impact

Shares likely face two-way volatility, with initial biotech-readthrough support offset by sell-side pressure from the concurrent equity offering.

Evidence & confidence

The article ties the surge to the Phase 3 survival readout, then notes after-hours weakness following the $150M offering, implying the market is balancing efficacy optimism against dilution and execution risk.

Market effects

Reinforces high sensitivity of small-cap biotech valuations to Phase 3 topline readouts, while highlighting how immediate equity issuance can cap follow-through.

Limited, primarily affecting US small-cap biotech sentiment rather than broad indices.

Low, as the catalyst is company-specific clinical data and a US equity offering.

Counterpoint

The survival benefit may be overstated versus active comparators because the control arm includes observation, and the trial’s statistical precision is thin without confidence intervals.

Key entities

  • SELLAS

    Subject of the article; shares surged after Phase 3 REGAL survival results and then sold off after a same-day $150M offering.

  • galinpepimut-S (GPS)

    Leukemia vaccine evaluated in Phase 3 REGAL; reported to reduce risk of death versus best available treatment.

  • REGAL trial

    Phase 3 study in AML; reported median overall survival 24.0 months vs 14.7 months, HR 0.59, p=0.035.

  • $150 million underwritten offering

    Same-day equity offering led by J.P. Morgan and TD Cowen, with a 30-day option for additional shares.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here

Sellas Life Sciences (SLS) reported positive Phase 3 trial results for its cancer vaccine, Galinpepimut-S (GPS), showing a 24-month median survival vs. 14.7 months in the control group. The company plans to meet with the FDA and aims to file for approval in early 2027. SLS also announced a $150M share offering to fund further development. Analysts and investors reacted positively, with some noting potential for expedited approval and broader applications.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 Winners This Year — Can Sellas Deliver Another Double From Here?

Sellas Life Sciences (SLS) stock surged 156% to $19.15 after positive Phase 3 trial results for its leukemia vaccine, Galinpepimut-S. The trial showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months in the control group. Maxim Group raised its price target to $40, citing significant upside potential. SLS is planning a $150M share offering to fund further development.